title: Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis.
abstract: BACKGROUND
  The aim of this study was to assess the efficacy, tolerability and safety of risedronate in adults with CF.
  
  
  METHODS
  Patients with a lumbar spine (LS), total hip (TH) or femoral neck (FN) bone mineral density (BMD) Z-score of -1 or less were randomised to receive risedronate 35 mg weekly or placebo, and calcium (1g)+vitamin D(3) (800IU).
  
  
  RESULTS
  At baseline, BMD Z-scores in the risedronate (n=17) and placebo (n=19) groups were similar. By 24 months, 7/17 risedronate patients vs 0/19 placebo patients stopped the study medication due to bone pain. After 24 months treatment, the mean difference (95% CI) in change in LS, TH and FN BMD between the risedronate vs placebo groups was 4.3% (0.4, 8.2) p=0.03; 4.0% (-0.5, 8.6) p=0.08; and 2.4% (-3.5, 8.2) p=0.41.
  
  
  CONCLUSIONS
  After two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo.
authors.affiliation: Adult Cystic Fibrosis Centre, Papworth Hospital, Cambridge, CB23 3RE, UK. charles.haworth@papworth.nhs.uk
authors.forename: Charles S
authors.initials: CS
authors.lastname: Haworth
authors.forename: Linda
authors.initials: L
authors.lastname: Sharples
authors.forename: Vikki
authors.initials: V
authors.lastname: Hughes
authors.forename: Sarah L
authors.initials: SL
authors.lastname: Elkin
authors.forename: Margaret E
authors.initials: ME
authors.lastname: Hodson
authors.forename: Steven P
authors.initials: SP
authors.lastname: Conway
authors.forename: Christine
authors.initials: C
authors.lastname: Etherington
authors.forename: J Stuart
authors.initials: JS
authors.lastname: Elborn
authors.forename: Jackie
authors.initials: J
authors.lastname: Rendall
authors.forename: Ella
authors.initials: E
authors.lastname: Wheaton
authors.forename: Emma
authors.initials: E
authors.lastname: Kadri
authors.forename: Jane
authors.initials: J
authors.lastname: Elliott
authors.forename: Helen C
authors.initials: HC
authors.lastname: Barker
authors.forename: Philip W P
authors.initials: PW
authors.lastname: Bearcroft
authors.forename: Thinn
authors.initials: T
authors.lastname: Hlaing
authors.forename: Juliet E
authors.initials: JE
authors.lastname: Compston
mesh_terms: D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000494:pharmacology; D003550:Cystic Fibrosis; D004334:Drug Administration Schedule; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D000068296:Risedronic Acid; D016037:Single-Blind Method
chemical_list: D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid